VALBIOTIS Presents Positive Results From a Study on TOTUM-63, Active Substance of VALEDIA®, Conducted by the CarMeN Laboratory in Lyon, at the Annual Meeting of the European Association for the Study of Diabetes (EASD)
VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, today announced the presentation of a preclinical study conducted by the CarMeN laboratory on the active substance TOTUM-63, at the 55th Annual Meeting of the European Association for the Study of Diabetes being held September 16-20, 2019 in Barcelona, Spain.
This preclinical study evaluated the effect of TOTUM-63 on the secretion of certain hormones which play a fundamental role in glucose metabolism. In a murine model of metabolic disease, TOTUM-63 completely corrected insulin, glucagon and GLP-1 (Glucagon-Like Peptide-1) concentrations in the portal vein, in response to a glucose intake. These three hormones are central to the regulation of blood glucose.
This study confirms, via an independent laboratory, the effects already demonstrated1 on blood glucose and weight by TOTUM-63, the active substance of VALEDIA®, a product designed to control blood glucose in prediabetics.
Béatrice MORIO-LIONDORE*, Research Director at the CarMeN Research Laboratory, comments: "We are delighted to be presenting this study at the 55th EASD Annual Meeting. The results obtained demonstrate the significant effects of TOTUM-63 on weight and glucose metabolism in this preclinical model. In addition, our study aimed to evaluate the effect of TOTUM-63 on the hormonal imbalances associated with metabolic diseases. We have proven that TOTUM-63 corrects the blood levels of three key hormones in glucose metabolism: insulin and glucagon, secreted by the pancreas, as well as GLP- 1, an intestinal hormone essential for blood glucose control that is well-known in the field of diabetes."
Pascal SIRVENT, Head of Discovery and Preclinical and Translational Research at VALBIOTIS adds: "The results obtained by the CarMeN laboratory team have high value for VALBIOTIS: by examining the hormonal level, this study has made a fundamental contribution to increasing our understanding of the action of TOTUM-63 on metabolism. The hormonal effects reported today are consistent with the improvement in metabolic parameters that have already been widely observed, both in preclinical and clinical studies with TOTUM-63. These results provide clear evidence of the positive action of TOTUM-63 on the levels of hormones whose secretion is altered in prediabetes or diabetes."
The poster of this study is available on the VALBIOTIS website: https://www.valbiotis.com/en/scientific-publications/
ABOUT THE CARMEN LABORATORY
The CarMeN laboratory - INSERM U1060 / INRA U1397 / INRA U1397 / Lyon1 University / INSA Lyon (directed by Hubert VIDAL) is a biomedical research laboratory in the fields of cardiovascular diseases, metabolism, diabetes and nutrition. It is a center of excellence, based in Lyon, that brings together the leading minds in research in the fields of metabolism, nutrition and cardiovascular diseases. With approximately 180 collaborators, including researchers, teachers and hospital practitioners, the CarMeN laboratory is supported by state-of-the-art technological (genomics, lipidomics, imaging) and clinical (CRNH, CIC) research platforms, providing a unique environment for conducting valuable translational research.
*Béatrice MORIO-LIONDORE is INRA Research Director for Team 3 ("Organelle communication and diabetes" headed by Jennifer RIEUSSET and Charles THIVOLET) of the CarMeN research laboratory and previously led a team working on obesity in the Human Nutrition Unit in Clermont-Ferrand. She has published more than 90 articles and journals.
About TOTUM-63, the active ingredient of VALEDIA®
Prediabetes is a growing public health problem worldwide, recognized by international organizations such as the WHO, the American Diabetes Association and the International Diabetes Federation, among others. Without effective treatment, 70% to 90% of prediabetic patients will develop type 2 diabetes.
VALEDIA® is the first clinically validated product specifically designed to help prediabetics reduce their risk of developing type 2 diabetes. VALEDIA® is the only product that contains the active ingredient TOTUM-63, a unique and patented combination of 5 plant extracts that act in synergy to target the physiopathological mechanisms of type 2 diabetes.
TOTUM-63 has already shown perfect tolerance and safety during a Phase I/II clinical study conducted in healthy volunteers. The results of the Phase IIA international randomized, placebo-controlled study showed that in patients with prediabetes, TOTUM-63 reduces fasting blood glucose and blood glucose at 2 hours, two risk factors of type 2 diabetes. In these subjects, who also presented with hypertriglyceridemia and abdominal obesity, TOTUM-63 significantly reduced body weight, waist circumference, blood triglycerides, blood LDL cholesterol, Fatty Liver Index and arterial hypertension.
VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled VALBIOTIS to benefit from strong financial leverage thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. VALBIOTIS has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS:
ISIN code: FR0013254851
Mnemonic code: ALVAL
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2019 (application number R 19-030). This document is available on the Company's website (www.valbiotis.com). VALBIOTIS does not accept any liability regarding the update or revision of these forward-looking statements.
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
1 See press release of 3 July 2019: https://www.valbiotis.com/app/uploads/2019/07/2019-06-21-PR_VALBIOTIS_PHASEIIA-VALEDIA.pdf
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
Rebecca John / Patrick Till
+1 646 378 2935
+33 1 56 88 11 14
Guillaume De Chamisso
+33 6 85 91 32 56
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
With Putin’s Visit, UAE Takes Spotlight in the New World Order14.10.2019 08:21:00 CEST | Press release
Watermelon Communications -- Patrick Michael, a commentator on the Middle East, wrote: Energy, Strategy, and Security; these three parameters have defined and shaped Russia-Middle East relations in the post-Cold War era. At a microcosmic level, this also applies in the case of UAE-Russia ties. While energy creates interdependence and makes partnership the only viable option on the table, security and strategy continues to be an entangled web. As Putin embarks on another significant visit to the Gulf – essentially UAE and Saudi Arabia – it’s time to revisit the three parameters. A good starting point is the conversion of views and strategies on energy supplies. A broad agreement over the output cut is critical considering the pressure on oil prices in the wake of a slowing global economy. There’s nothing more fruitful for the industry and the economy than the big suppliers working in coordination and Russia “deeply values the significant contribution the UAE is making to the global oil
Metanoia Announces Its Next Generation Broadband Access Technology14.10.2019 07:11:00 CEST | Press release
BROADBAND WORLD FORUM 2019--In order to respond to the ever increasing demand for higher data rate of xDSL over copper, coax lines, Metanoia Communications (“Metanoia”) announced today the launch of its latest family of chipsets that supports all the ITU-T Gfast (212MHz profile) and VDSL2 (35MHz profile) standards and builds on Metanoia’s proven Gfast, VDSL2 and ADSL2/2+ technology. With its MT-x2331 product family, Metanoia will deliver the industry first next generation broadband access xDSL PHY chipset for multiple applications including home gateways, low density xDSL Central Office systems and standalone xDSL termination, such as SFP modules. Emerging trends in the Broadband Access Networks make the use of standalone xDSL PHY solution more pertinent for WAN PHY agnostic platforms. A standalone xDSL PHY enables cost-effective upgrade of existing WAN deployments, an approach which is increasingly attractive to Operators. Metanoia MT-x2331 series is a chipset family that supports all
BIZCENTER USA Launches Coworking Facility in Orlando With Plans for Nationwide Franchise14.10.2019 04:01:00 CEST | Press release
Multimedia, Inc. (www.multimediausa.com) starts today the operations of BIZCENTER USA LLC, its affiliate for shared workspaces and virtual offices. Located on a fully owned 4,400 sq. ft. area in one of the most strategic regions of Orlando, Florida, BIZCENTER USA is offering brand-new state of the art executive suites in a facility with upscale conference rooms, reception, luxury lounge, and kitchen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191013005018/en/ Founded in Orlando in 1991, Multimedia is a leading marketing and communications company, highly recognized worldwide for its professional integrity, serving advertising agencies, direct clients and media outlets across all continents. According to Fernando Mariano, president of both companies, the creation of BIZCENTER USA fulfills the needs for a stylish shared workspace and virtual office facility in Southwest Orlando. “Multimedia has strong ties with the Orlando
Vodafone Idea and Mavenir Partner to Extend Network as a Platform14.10.2019 01:00:00 CEST | Press release
Mavenir, the industry's only end-to-end cloud-native 4G and 5G network software provider for CSPs today announced the extension of its partnership with Vodafone Idea Limited (VIL), India’s leading telecom operator, to extend VIL Network as a Platform, reaching distributed presence across all the major Industrial, Commercial, and Services clusters in India. This partnership will focus on three thrust areas. First, building a universal secured Cloud capable of hosting multiple tenants and third-party applications. Second, building a fully automated platform that enables self-provisioning of various workloads. Third and most importantly, setting up a joint innovation lab and team that will consistently innovate on Chipset, Operating System, and work at Application level to offer unique APIs and enable new use cases and delightful experience to VIL customers. “Vodafone Idea has the largest Edge Cloud deployment in India. Our partnership with Mavenir will enable continued innovation in opti
SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CEST | Press release
SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti
Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CEST | Press release
In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs